Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,784 GBX | -1.60% | +0.17% | +22.98% |
05:41am | GSK to Sell Remaining Haleon Stake | MT |
May. 16 | GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update | DJ |
Sales 2024 * | 31.61B 40.02B | Sales 2025 * | 33.56B 42.48B | Capitalization | 72.73B 92.06B |
---|---|---|---|---|---|
Net income 2024 * | 5.54B 7.02B | Net income 2025 * | 6.49B 8.22B | EV / Sales 2024 * | 2.69 x |
Net Debt 2024 * | 12.3B 15.57B | Net Debt 2025 * | 9.1B 11.52B | EV / Sales 2025 * | 2.44 x |
P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
11.3
x | Employees | 70,212 |
Yield 2024 * |
3.42% | Yield 2025 * |
3.55% | Free-Float | 94.54% |
Latest transcript on GSK plc
1 day | -1.60% | ||
1 week | +0.17% | ||
Current month | +6.60% | ||
1 month | +10.74% | ||
3 months | +6.39% | ||
6 months | +29.05% | ||
Current year | +22.98% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 17 M€ | +7.83% | - | |
2.51% | 7 M€ | +9.05% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 1,784 | -1.60% | 5,275,162 |
24-05-15 | 1,812 | +0.14% | 4,861,330 |
24-05-14 | 1,810 | 0.00% | 4,739,267 |
24-05-13 | 1,810 | +0.58% | 4,236,369 |
24-05-10 | 1,800 | +1.07% | 9,331,038 |
Delayed Quote London S.E., May 16, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.98% | 93.64B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- GSK Stock